Dr Sean O'Cathail

  • Clinical Senior Lecturer (Clinical Trials Research)

email: Sean.OCathail@glasgow.ac.uk

RI Cancer Sciences, Wolfson Wohl Cancer Research Centre, Garscube Campus, Bearsden, Glasgow, G61 1BD

ORCID iDhttps://orcid.org/0000-0001-5574-9199

Publications

List by: Type | Date

Jump to: 2021 | 2020 | 2019 | 2018 | 2017 | 2015 | 2014 | 2013 | 2012 | 2011
Number of items: 23.

2021

O'Cathail, S. M. , Wu, C.-H., Thomas, R., Hawkins, M. A., Maughan, T. S. and Lewis, A. (2021) NRF2 mediates therapeutic resistance to chemoradiation in colorectal cancer through a metabolic switch. Antioxidants, 10(9), 1380. (doi: 10.3390/antiox10091380)

Hanna, C. R. et al. (2021) Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology, 16, 163. (doi: 10.1186/s13014-021-01888-1) (PMID:34446053)

Hanna, C. R. et al. (2021) Intensity modulated radiotherapy for rectal cancer in the UK in 2020. Clinical Oncology, 33(4), pp. 213-223. (doi: 10.1016/j.clon.2020.12.011) (PMID:33423883)

Hanna, C. R. , O'Cathail, S. M. , Graham, J., Adams, R. and Roxburgh, C. S.D. (2021) Immune checkpoint inhibition as a strategy in the neoadjuvant treatment of locally advanced rectal cancer. Journal of Immunotherapy and Precision Oncology, 4(2), (doi: 10.36401/JIPO-20-31)

2020

Smith, T., O'Cathail, S. M. , Silverman, S., Robinson, M., Tsang, Y., Harrison, M. and Hawkins, M. A. (2020) Stereotactic Body Radiotherapy re-irradiation for locally recurrent rectal cancer: outcomes and toxicity. Advances in Radiation Oncology, 5(6), pp. 1311-1319. (doi: 10.1016/j.adro.2020.07.017) (PMID:33305093) (PMCID:PMC7718547)

O'Cathail, S. M. , Smith, T., Owens, R., Zeniou, A., Tsang, Y., Holyoake, D. L.P., Murray, L., Harrison, M. and Hawkins, M. A. (2020) Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy. Radiotherapy and Oncology, 151, pp. 280-286. (doi: 10.1016/j.radonc.2020.08.012) (PMID:32866563) (PMCID:PMC7689579)

O'Cathail, S. M. , Wu, C.-H., Lewis, A., Holmes, C., Hawkins, M. A. and Maughan, T. (2020) NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer. Cancer Genetics, 248, pp. 1-10. (doi: 10.1016/j.cancergen.2020.08.006) (PMID:32871287)

O'Cathail, S.M. , Gilbert, D.C., Sebag-Montefiore, D. and Muirhead, R. (2020) Challenges and consequences of COVID-19 in the management of anorectal cancer: coming together through social distancing. Clinical Oncology, 32(7), pp. 413-416. (doi: 10.1016/j.clon.2020.04.009) (PMID:32359847) (PMCID:PMC7184022)

O'Cathail, S. M. et al. (2020) A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR). Radiation Oncology, 15, 151. (doi: 10.1186/s13014-020-01593-5) (PMID:32532291) (PMCID:PMC7291514)

Cooke, R., Camilleri, P., Chu, K.-Y., O'Cathail, S. M. , Robinson, M., Van Den Heuvel, F. and Hawkins, M. A. (2020) Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: initial outcomes. Technical Innovations and Patient Support in Radiation Oncology, 13, pp. 24-30. (doi: 10.1016/j.tipsro.2020.01.002) (PMID:32128460) (PMCID:PMC7042153)

2019

Rayner, E., Durin, M.-A., Thomas, R., Moralli, D., O'Cathail, S. M. , Tomlinson, I., Green, C. M. and Lewis, A. (2019) CRISPR-Cas9 causes chromosomal instability and rearrangements in cancer cell lines, detectable by cytogenetic methods. CRISPR Journal, 2(6), pp. 406-416. (doi: 10.1089/crispr.2019.0006) (PMID:31742432) (PMCID:PMC6919265)

O'Cathail, S.M. and Buffa, F.M. (2019) Science in focus: bioinformatics part 1 – lost in translation. Clinical Oncology, 31(6), pp. 337-340. (doi: 10.1016/j.clon.2019.03.043) (PMID:30975523)

2018

O'Cathail, S. M. , Karir, N. and Shah, K. (2018) Optimising volumetric arc radiotherapy for dental rehabilitation in oropharynx cancer – a retrospective dosimetry review and feasibility planning study. Oral Oncology, 76, pp. 16-21. (doi: 10.1016/j.oraloncology.2017.11.020) (PMID:29290281)

2017

O'Cathail, S. M. , Pokrovska, T. D., Maughan, T. S., Fisher, K. D., Seymour, L. W. and Hawkins, M. A. (2017) Combining oncolytic adenovirus with radiation—a paradigm for the future of radiosensitization. Frontiers in Oncology, 7, 153. (doi: 10.3389/fonc.2017.00153) (PMID:28791251) (PMCID:PMC5523729)

Muirhead, R., Drinkwater, K., O'Cathail, S.M. , Adams, R., Glynne-Jones, R., Harrison, M., Hawkins, M.A., Sebag-Montefiore, D. and Gilbert, D.C. (2017) Initial results from the Royal College of Radiologists' UK national audit of anal cancer radiotherapy 2015. Clinical Oncology, 29(3), pp. 188-197. (doi: 10.1016/j.clon.2016.10.005) (PMID:27810119) (PMCID:PMC5304408)

Cox, S. J., O'Cathail, S. M. , Coles, B., Crosby, T. and Mukherjee, S. (2017) Update on neoadjuvant regimens for patients with operable oesophageal/gastrooesophageal junction adenocarcinomas and squamous cell carcinomas. Current Oncology Reports, 19(1), 7. (doi: 10.1007/s11912-017-0559-8) (PMID:28213876) (PMCID:PMC5315732)

2015

Higgins, G. S., O'Cathail, S. M. , Muschel, R. J. and McKenna, W. G. (2015) Drug radiotherapy combinations: review of previous failures and reasons for future optimism. Cancer Treatment Reviews, 41(2), pp. 105-113. (doi: 10.1016/j.ctrv.2014.12.012) (PMID:25579753)

2014

Ramaswami, R., O'Cathail, S. M. , Brindley, J. H., Silcocks, P., Mahmoud, S. and Palmieri, C. (2014) Activity of eribulin mesylate in heavily pretreated breast cancer granted accessvia the Cancer Drugs Fund. Future Oncology, 10(3), pp. 363-376. (doi: 10.2217/fon.13.210) (PMID:24367990)

Stavraka, C., Pinato, D. J., Turnbull, S. J., Flynn, M. J., Forster, M. D., O'Cathail, S. M. , Babar, S., Seckl, M. J., Kristeleit, R. S. and Blagden, S. P. (2014) Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials. Cancer, 120(2), pp. 262-270. (doi: 10.1002/cncr.28381) (PMID:24399418)

Scarpa, A. et al. (2014) An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials. PLoS ONE, 9(1), e83279. (doi: 10.1371/journal.pone.0083279) (PMID:24409281) (PMCID:PMC3883636)

2013

O'Cathail, S. M. , Shaboodien, R., Mahmoud, S., Carty, K., O'Sullivan, P., Blagden, S., Gabra, H., Whear, S., Kwon, J. S. and Agarwal, R. (2013) Intravenous versus oral dexamethasone premedication in preventing paclitaxel infusion hypersensitivity reactions in gynecological malignancies. International Journal of Gynecologic Cancer, 23(7), pp. 1318-1325. (doi: 10.1097/IGC.0b013e31829f1799) (PMID:23907557)

2012

O'Cathail, S. and Stebbing, J. (2012) Ayurveda: alternative or complementary? Lancet Oncology, 13(9), p. 865. (doi: 10.1016/S1470-2045(12)70405-9) (PMID:22935233)

2011

O'Cathail, S.M. , O'Connell, O.J., Long, N., Morgan, M., Eustace, J.A., Plant, B.J. and Hourihane, J.O.'.B. (2011) Association of cigarette smoking with drug use and risk taking behaviour in Irish teenagers. Addictive Behaviors, 36(5), pp. 547-550. (doi: 10.1016/j.addbeh.2011.01.012) (PMID:21315520)

This list was generated on Tue Sep 28 23:41:07 2021 BST.
Jump to: Articles
Number of items: 23.

Articles

O'Cathail, S. M. , Wu, C.-H., Thomas, R., Hawkins, M. A., Maughan, T. S. and Lewis, A. (2021) NRF2 mediates therapeutic resistance to chemoradiation in colorectal cancer through a metabolic switch. Antioxidants, 10(9), 1380. (doi: 10.3390/antiox10091380)

Hanna, C. R. et al. (2021) Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology, 16, 163. (doi: 10.1186/s13014-021-01888-1) (PMID:34446053)

Hanna, C. R. et al. (2021) Intensity modulated radiotherapy for rectal cancer in the UK in 2020. Clinical Oncology, 33(4), pp. 213-223. (doi: 10.1016/j.clon.2020.12.011) (PMID:33423883)

Hanna, C. R. , O'Cathail, S. M. , Graham, J., Adams, R. and Roxburgh, C. S.D. (2021) Immune checkpoint inhibition as a strategy in the neoadjuvant treatment of locally advanced rectal cancer. Journal of Immunotherapy and Precision Oncology, 4(2), (doi: 10.36401/JIPO-20-31)

Smith, T., O'Cathail, S. M. , Silverman, S., Robinson, M., Tsang, Y., Harrison, M. and Hawkins, M. A. (2020) Stereotactic Body Radiotherapy re-irradiation for locally recurrent rectal cancer: outcomes and toxicity. Advances in Radiation Oncology, 5(6), pp. 1311-1319. (doi: 10.1016/j.adro.2020.07.017) (PMID:33305093) (PMCID:PMC7718547)

O'Cathail, S. M. , Smith, T., Owens, R., Zeniou, A., Tsang, Y., Holyoake, D. L.P., Murray, L., Harrison, M. and Hawkins, M. A. (2020) Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy. Radiotherapy and Oncology, 151, pp. 280-286. (doi: 10.1016/j.radonc.2020.08.012) (PMID:32866563) (PMCID:PMC7689579)

O'Cathail, S. M. , Wu, C.-H., Lewis, A., Holmes, C., Hawkins, M. A. and Maughan, T. (2020) NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer. Cancer Genetics, 248, pp. 1-10. (doi: 10.1016/j.cancergen.2020.08.006) (PMID:32871287)

O'Cathail, S.M. , Gilbert, D.C., Sebag-Montefiore, D. and Muirhead, R. (2020) Challenges and consequences of COVID-19 in the management of anorectal cancer: coming together through social distancing. Clinical Oncology, 32(7), pp. 413-416. (doi: 10.1016/j.clon.2020.04.009) (PMID:32359847) (PMCID:PMC7184022)

O'Cathail, S. M. et al. (2020) A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR). Radiation Oncology, 15, 151. (doi: 10.1186/s13014-020-01593-5) (PMID:32532291) (PMCID:PMC7291514)

Cooke, R., Camilleri, P., Chu, K.-Y., O'Cathail, S. M. , Robinson, M., Van Den Heuvel, F. and Hawkins, M. A. (2020) Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: initial outcomes. Technical Innovations and Patient Support in Radiation Oncology, 13, pp. 24-30. (doi: 10.1016/j.tipsro.2020.01.002) (PMID:32128460) (PMCID:PMC7042153)

Rayner, E., Durin, M.-A., Thomas, R., Moralli, D., O'Cathail, S. M. , Tomlinson, I., Green, C. M. and Lewis, A. (2019) CRISPR-Cas9 causes chromosomal instability and rearrangements in cancer cell lines, detectable by cytogenetic methods. CRISPR Journal, 2(6), pp. 406-416. (doi: 10.1089/crispr.2019.0006) (PMID:31742432) (PMCID:PMC6919265)

O'Cathail, S.M. and Buffa, F.M. (2019) Science in focus: bioinformatics part 1 – lost in translation. Clinical Oncology, 31(6), pp. 337-340. (doi: 10.1016/j.clon.2019.03.043) (PMID:30975523)

O'Cathail, S. M. , Karir, N. and Shah, K. (2018) Optimising volumetric arc radiotherapy for dental rehabilitation in oropharynx cancer – a retrospective dosimetry review and feasibility planning study. Oral Oncology, 76, pp. 16-21. (doi: 10.1016/j.oraloncology.2017.11.020) (PMID:29290281)

O'Cathail, S. M. , Pokrovska, T. D., Maughan, T. S., Fisher, K. D., Seymour, L. W. and Hawkins, M. A. (2017) Combining oncolytic adenovirus with radiation—a paradigm for the future of radiosensitization. Frontiers in Oncology, 7, 153. (doi: 10.3389/fonc.2017.00153) (PMID:28791251) (PMCID:PMC5523729)

Muirhead, R., Drinkwater, K., O'Cathail, S.M. , Adams, R., Glynne-Jones, R., Harrison, M., Hawkins, M.A., Sebag-Montefiore, D. and Gilbert, D.C. (2017) Initial results from the Royal College of Radiologists' UK national audit of anal cancer radiotherapy 2015. Clinical Oncology, 29(3), pp. 188-197. (doi: 10.1016/j.clon.2016.10.005) (PMID:27810119) (PMCID:PMC5304408)

Cox, S. J., O'Cathail, S. M. , Coles, B., Crosby, T. and Mukherjee, S. (2017) Update on neoadjuvant regimens for patients with operable oesophageal/gastrooesophageal junction adenocarcinomas and squamous cell carcinomas. Current Oncology Reports, 19(1), 7. (doi: 10.1007/s11912-017-0559-8) (PMID:28213876) (PMCID:PMC5315732)

Higgins, G. S., O'Cathail, S. M. , Muschel, R. J. and McKenna, W. G. (2015) Drug radiotherapy combinations: review of previous failures and reasons for future optimism. Cancer Treatment Reviews, 41(2), pp. 105-113. (doi: 10.1016/j.ctrv.2014.12.012) (PMID:25579753)

Ramaswami, R., O'Cathail, S. M. , Brindley, J. H., Silcocks, P., Mahmoud, S. and Palmieri, C. (2014) Activity of eribulin mesylate in heavily pretreated breast cancer granted accessvia the Cancer Drugs Fund. Future Oncology, 10(3), pp. 363-376. (doi: 10.2217/fon.13.210) (PMID:24367990)

Stavraka, C., Pinato, D. J., Turnbull, S. J., Flynn, M. J., Forster, M. D., O'Cathail, S. M. , Babar, S., Seckl, M. J., Kristeleit, R. S. and Blagden, S. P. (2014) Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials. Cancer, 120(2), pp. 262-270. (doi: 10.1002/cncr.28381) (PMID:24399418)

Scarpa, A. et al. (2014) An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials. PLoS ONE, 9(1), e83279. (doi: 10.1371/journal.pone.0083279) (PMID:24409281) (PMCID:PMC3883636)

O'Cathail, S. M. , Shaboodien, R., Mahmoud, S., Carty, K., O'Sullivan, P., Blagden, S., Gabra, H., Whear, S., Kwon, J. S. and Agarwal, R. (2013) Intravenous versus oral dexamethasone premedication in preventing paclitaxel infusion hypersensitivity reactions in gynecological malignancies. International Journal of Gynecologic Cancer, 23(7), pp. 1318-1325. (doi: 10.1097/IGC.0b013e31829f1799) (PMID:23907557)

O'Cathail, S. and Stebbing, J. (2012) Ayurveda: alternative or complementary? Lancet Oncology, 13(9), p. 865. (doi: 10.1016/S1470-2045(12)70405-9) (PMID:22935233)

O'Cathail, S.M. , O'Connell, O.J., Long, N., Morgan, M., Eustace, J.A., Plant, B.J. and Hourihane, J.O.'.B. (2011) Association of cigarette smoking with drug use and risk taking behaviour in Irish teenagers. Addictive Behaviors, 36(5), pp. 547-550. (doi: 10.1016/j.addbeh.2011.01.012) (PMID:21315520)

This list was generated on Tue Sep 28 23:41:07 2021 BST.